Recombinant Oncolytic Virus M1 for Injection (Guangzhou Virotech Pharmaceutical Co Ltd)

注射用重组溶瘤病毒M1 (广州威溶特医药科技有限公司)

Report date: 2026/05/18 20:02:07

Base Information

Drug NameRecombinant Oncolytic Virus M1 for Injection (Guangzhou Virotech Pharmaceutical Co Ltd)

Drug Alias NameRecombinant oncolytic virus based on the backbone of Alphavirus M1 (Guangzhou Virotech Pharmaceutical Co Ltd)Recombinant Oncolytic Virus M1 (Guangzhou Virotech Pharmaceutical Co Ltd)VRT-106M1-c6v1

ClassificationBiologics > Oncolytic virus

Mechanisms of ActionCell death stimulants

TargetsNot applicable

Therapy Area/IndicationsSolid tumoursDiffuse midline gliomaPancreatic Neoplasms +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland ChinaJapan

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

Originator CompaniesGuangzhou Virotech Pharmaceutical Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Virotech Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursDiffuse midline gliomaPancreatic Neoplasms +[6]

Inactive IndicationsN/A

Other Information

ATC CodeN/A